Black Diamond Therapeutics Inc (nasdaq:BDTX) Share Price

Company Profile

Business description
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
Contact
245 First Street
18th Floor
CambridgeMA02142
USA
T: +1 617 252-0848
https://www.blackdiamondtherapeutics.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
21

Recommended

Shares jumped 9% after earnings, as stronger AI memory prices boosted the chipmaker’s outlook.

Jing Jie Yu | 28 October 2026

Concerns about equity sales to finance AI investments have pressured shares.

Malik Ahmed Khan, CFA | 28 October 2026

AI data center revenue is growing fast, but questions about durability remain.

Nicolas Owens | 28 October 2026

Index	Last price	Change	% Change
All Ordinaries	9,012.60	41.20	0.46%
CAC 40	7,973.55	86.59	1.10%
DAX 40	25,995.90	291.88	1.14%
Dow JONES (US)	52,475.10	97.53	0.19%
FTSE 100	10,733.30	38.80	0.36%
HKSE	22,958.65	136.18	-0.59%
NASDAQ	26,549.85	72.04	0.27%
Nikkei 225	64,659.47	705.28	1.10%
NZX 50 Index	13,710.17	18.84	0.14%
S&P 500	7,743.98	21.38	0.28%
S&P/ASX 200	8,891.80	44.50	0.50%
SSE Composite Index	3,651.43	30.04	-0.82%